Connect to share and comment

Should pharmaceuticals be able to hold long-term patents on drugs?

India's Supreme Court on Monday denied pharmaceutical giant Novartis' patent application for a new version of the cancer drug Gleevec (also spelled Glivec), enabling Indian generic drug makers to keep producing cheaper copycat versions. Generic drug advocates hailed this as a landmark case that will bring medicine to poor patients, while Novartis said the decision will discourage private investment in innovation.